300119 瑞普生物
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)5.41110.3918.40112.72417.398
总资产报酬率 ROA (%)3.4887.1325.8788.60910.672
投入资产回报率 ROIC (%)4.1638.3166.80010.13713.067

边际利润分析
销售毛利率 (%)49.39349.68748.44151.80454.040
营业利润率 (%)17.40825.13319.99024.87925.651
息税前利润/营业总收入 (%)18.34326.04020.68625.23826.818
净利润/营业总收入 (%)15.12422.72217.93321.60221.970

收益指标分析
经营活动净收益/利润总额(%)92.62266.11085.14072.81079.075
价值变动净收益/利润总额(%)8.29213.48413.39627.11523.146
营业外收支净额/利润总额(%)-0.5920.256-0.683-2.372-0.431

偿债能力分析
流动比率 (X)1.9232.4262.3622.7241.829
速动比率 (X)1.6992.1372.0812.4041.414
资产负债率 (%)33.32427.15426.28724.0240.298
带息债务/全部投入资本 (%)22.41917.97417.48515.51917.139
股东权益/带息债务 (%)332.332442.670460.543524.461449.265
股东权益/负债合计 (%)183.616251.042262.994294.971211.284
利息保障倍数 (X)17.68230.92024.85526.96820.992

营运能力分析
应收账款周转天数 (天)152.685134.895113.60091.10171.166
存货周转天数 (天)119.139120.421121.862134.805122.881